Five Prime Therapeutics, Inc.

Bristol-myers Squibb Compnay

Other

Paladin Brands Group, Inc.

Robert Sikorski

Julie Hambleton

Emma Masteller

Brian Wong

Katherine E Lewis

Kevin Hestir

David Bellovin

Janine Powers

Nilacantan Sankar

Ernestine A Lee

Anthony G Seda

Majid Ghoddusi

Kristen Pierce

Penny E Phillips

Hong Xiang

Servando Palencia

Michael Carleton

Kartik Sundareshwar Krishnan

James Zanghi

Serena Kimi Perna

Ke Xu

Dimple Pandya

Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.

FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.

Method of treating PVNS with anti-CSF1R antibodies

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Anti-CSF1R antibodies for treating PVNS

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

Growing community of inventors

Woodside, CA, United States of America

Robert Sikorski